Aquestive Therapeutics
AQST
57 hedge funds and large institutions have $48.1M invested in Aquestive Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 5 closing their positions.
294% more call options, than puts
Call options by funds: $339K | Put options by funds: $86K
200% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 5
124% more capital invested
Capital invested by funds: $21.5M → $48.1M (+$26.6M)
31% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 13
21% more funds holding
Funds holding: 47 → 57 (+10)
1.42% more ownership
Funds ownership: 34.24% → 35.66% (+1.4%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.5M |
| 2 |
LCM
Legato Capital Management
San Francisco,
California
|
+$602K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$336K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$292K |
| 5 |
Jane Street
New York
|
+$276K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.55M |
| 2 |
Corient Private Wealth
Miami,
Florida
|
-$470K |
| 3 |
VAFP
Vahanian & Associates Financial Planning
Saratoga Springs,
New York
|
-$231K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$154K |
| 5 |
Squarepoint
New York
|
-$116K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $8.8K | -$11.5K | -6,517 | -60% |
|
52
Federated Hermes
Pittsburgh,
Pennsylvania
| $4.95K | +$360 | +204 | +9% |
|
53
UBS Group
Zurich,
Switzerland
| $4.63K | +$4.05K | +2,290 | New |
|
|
RWPA
54
Richard W. Paul & Associates
Novi,
Michigan
| $2.88K | – | – | – |
|
|
PA
55
Parallel Advisors
San Francisco,
California
| $202 | +$177 | +100 | New |
|
|
CAS
56
Coppell Advisory Solutions
Coppell,
Texas
| $32 | -$37 | -21 | -57% |
|
57
BNP Paribas Financial Markets
Paris,
France
| $2 | – | – | – |
|
|
GCP
58
GSA Capital Partners
London,
United Kingdom
| – | -$154K | -100,854 | Closed |
|
|
59
Squarepoint
New York
| – | -$116K | -75,683 | Closed |
|
|
XT
60
XTX Topco
George Town,
Cayman Islands
| – | -$81.1K | -52,980 | Closed |
|
|
HBCM
61
Heron Bay Capital Management
Bloomfield Hills,
Michigan
| – | -$21.5K | -14,025 | Closed |
|
62
Barclays
London,
United Kingdom
| – | -$10.9K | -7,144 | Closed |
|
AQST Hedge Fund Activity: Q4 2023 in Review
57 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q4 2023, worth a combined $48.1M — up 124% from $21.5M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AQST positions and 5 closed out — a net gain of 10 holders — while 17 added to existing stakes and 13 trimmed.
The largest buyer was Essex Investment Management, opening a new position worth an estimated $1.5M. The largest seller was Armistice Capital, cutting an estimated $1.55M.
- 57 institutional investors held Aquestive Therapeutics (AQST) as of Q4 2023, up from 47 in Q3 2023.
- Funds reported $48.1M of Aquestive Therapeutics stock for Q4 2023, up 124% quarter-over-quarter.
- 15 funds opened new Aquestive Therapeutics positions in Q4 2023 and 5 closed out, a net change of +10 holders.
- The largest Aquestive Therapeutics buyer in Q4 2023 was Essex Investment Management, an estimated $1.5M added.
- The largest Aquestive Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $1.55M sold.
Based on aggregated 13F filings for Q4 2023.